当前位置:首页 - 行情中心 - 奥翔药业(603229) - 财务分析 - 现金流量表

奥翔药业

(603229)

  

流通市值:83.36亿  总市值:83.36亿
流通股本:8.30亿   总股本:8.30亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金124,035,737.44881,351,859.33659,187,022.28411,554,272.5
  收到的税费返还143,941.881,727,029.7--
  收到其他与经营活动有关的现金64,200,585.02101,167,997.760,824,871.625,108,839.99
  经营活动现金流入小计188,380,264.34984,246,886.73720,011,893.88436,663,112.49
  购买商品、接受劳务支付的现金99,316,564.87377,408,767.45294,171,951.15197,944,336.87
  支付给职工以及为职工支付的现金76,515,403.1211,547,810.19165,425,717.97109,096,442.47
  支付的各项税费4,635,845.7542,615,285.8941,043,301.0833,479,216.2
  支付其他与经营活动有关的现金41,947,428.61196,166,108.9571,725,311.3150,739,450.16
  经营活动现金流出的平衡项目000-0.01
  经营活动现金流出小计222,415,242.33827,737,972.48572,366,281.51391,259,445.69
  经营活动产生的现金流量净额-34,034,977.99156,508,914.25147,645,612.3745,403,666.8
二、投资活动产生的现金流量:
  取得投资收益收到的现金--19,243,464.16-
  处置固定资产、无形资产和其他长期资产收回的现金净额-109,013.45282,596.09282,596.09
  收到的其他与投资活动有关的现金8,887,293.0866,925,007.5228,562,110.5239,194,828.99
  投资活动现金流入小计8,887,293.0867,034,020.9748,088,170.7739,477,425.08
  购建固定资产、无形资产和其他长期资产支付的现金25,228,160.11104,445,390.3481,485,874.1553,803,090.69
  投资支付的现金--4,008,8162,004,408
  支付其他与投资活动有关的现金4,951,851.5721,011,807.9910,431,265.0211,994,265.02
  投资活动现金流出小计30,180,011.68125,457,198.3395,925,955.1767,801,763.71
  投资活动产生的现金流量净额-21,292,718.6-58,423,177.36-47,837,784.4-28,324,338.63
三、筹资活动产生的现金流量:
  取得借款收到的现金101,000,000505,180,810.84275,180,810.84229,390,810.84
  收到其他与筹资活动有关的现金602,116.4819,336,915.632,715,711.7117,198,981.95
  筹资活动现金流入小计101,602,116.48524,517,726.44307,896,522.55246,589,792.79
  偿还债务支付的现金71,045,810.84320,355,000170,294,767.18170,100,000
  分配股利、利润或偿付利息支付的现金3,337,074.7190,623,943.6288,318,438.423,519,572.69
  支付其他与筹资活动有关的现金19,589,149.3863,087,428.2114,400,313.3369,114,187.68
  筹资活动现金流出小计93,972,034.93474,066,371.82373,013,518.93242,733,760.37
  筹资活动产生的现金流量净额7,630,081.5550,451,354.62-65,116,996.383,856,032.42
四、汇率变动对现金及现金等价物的影响-22,048,408.04-17,457,141.89-2,547,447.625,776,044.16
五、现金及现金等价物净增加额-69,746,023.08131,079,949.6232,143,383.9726,711,404.75
  加:期初现金及现金等价物余额1,179,661,168.771,048,581,219.151,048,581,219.151,048,581,219.15
  期末现金及现金等价物余额1,109,915,145.691,179,661,168.771,080,724,603.121,075,292,623.9
补充资料:
  净利润-130,570,123.6-169,346,106.65
  资产减值准备-19,583,678.95-6,415,526.03
  固定资产和投资性房地产折旧-72,038,987.35-33,482,969.78
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-72,038,987.35-33,482,969.78
  无形资产摊销-2,150,081.02-1,113,789.73
  固定资产报废损失-1,482,914.86--
  公允价值变动损失-489,448.22--545,324.37
  财务费用-28,695,012.24--1,113,816.55
  投资损失--22,281,446.94--14,311,078.41
  递延所得税--3,359,175.1--908,668.17
  其中:递延所得税资产减少--3,359,175.1--908,668.17
  存货的减少--16,934,028.94--2,971,305.84
  经营性应收项目的减少--9,119,596.86--143,441,616.35
  经营性应付项目的增加--42,401,299.36--1,962,646.21
  其他--87,556.43--
  现金的期末余额-1,179,661,168.77-1,075,292,623.9
  减:现金的期初余额-1,048,581,219.15-1,048,581,219.15
  现金及现金等价物的净增加额-131,079,949.62-26,711,404.75
公告日期2026-04-292026-04-292025-10-312025-08-29
审计意见(境内)标准无保留意见
TOP↑